Table 1

Descriptive statistics per treatment (data set A)

AZACsA CYC FTY GLAT IFN IVIG Mitox MMF MTX NAT RTX Steroids i.th. Steroids p.o. TCZ
Patients receiving treatment, n461122173033485765552
Females, n (%)42 (91.3)1 (100)12 (100)2 (100)16 (94.1)25 (83.3)3 (100)26 (76.5)5 (62.5)5 (100)5 (71.4)54 (83.1)4 (80.0)4 (80.0)2 (100)
Age, mean (SD)43.8 (12.6)43.5 (8.5)47 (11.9)54.3 (3.4)40.5 (9.6)37.6 (11.4)41.1 (22.6)46.8 (13.4)53.2 (12.0)50.8 (11.9)48.4 (10.7)46.8 (12.8)46.2 (9)43.2 (16.4)39.2 (8.6)
Disease duration, mean (SD), years4.4 (6)13.4 (8.5)4.2 (5.9)18.6 (1.4)6.1 (5.8)5.7 (6.2)7.8 (7.9)5.4 (5.9)5.6 (6.0)5.6 (8.3)11.6 (9.1)4.8 (4.8)4.9 (5.1)2.7 (3.8)6 (2.3)
2006 Wingerchuk criteria fulfilled, n (%)33 (71.7)1 (100)10 (83.3)2 (100)14 (83.4)29 (96.7)2 (66.7)27 (79.4)6 (75.0)4 (80.0)7 (100)50 (76.9)4 (80.0)4 (80.0)2 (100)
AQP4-ab-positive, n (%)40 (87.0)1 (100)12 (100)1 (50)11 (64.7)27 (90.0)3 (100)30 (88.2)7 (87.5)4 (80.0)7 (100)57 (87.7)4 (80.0)4 (80.0)2 (100)
Treatment episodes n (%)52 (19.6)2 (0.8)14 (5.3)2 (0.6)17 (6.4)32 (12.1)3 (0.9)34 (12.8)8 (3.0)5 (1.9)7 (2.1)77 (29.1)5 (1.9)5 (1.9)2 (0.8)
Episodes without attack, %67.35071.45052.925.033.364.737.560.028.659.780.010050
First-line, n3109072722231228140
Second-line, n10030640923324311
Third-line or more, n11222411331225101
Rate of first-line treatments per drug, %59.6064.3041.284.466.764.737.520.028.636.420.080.00
Rate of drug as first-line in the cohort, %22.606.605.119.71.516.12.20.71.520.40.72.90
Treatment duration, mean (SD) days475 (477)291 (281)122 (125)77 (21)221 (186)699 (596)488 (331)345 (268)462 (447)363 (335)159 (104)524 (430)418 (309)165 (186)389 (4)
Cumulative treatment, years67.61.64.70.410.361.24.032.110.15.03.0110.55.72.32.1
Annualised attack rate, mean (95% CI)0.34 (0.22 0.51)0.63 (0.02 to 3.48)1.28 (0.47 to 2.78)2.37 (0.06 to 13.02)1.36 (0.74 to 2.28)0.75 (0.55 to 1.00)0.75 (0.15 to 2.18)0.84 (0.55 to 1.22)0.79 (0.34 to 1.55)0.40 (0.05–1.45)1.97 (0.73 to 4.28)0.46 (0.34 to 0.61)0.35 (0.04 to 1.26)0 (0. to 1.63)0.47 (0.01 to 2.61)
  • Age and disease duration at treatment start.

  • AZA, azathioprine; AQP4-ab, antibodies against aquaporin-4; CsA, ciclosporin A; CYC, cyclophosphamide; FTY, fingolimod; GLAT, glatiramer acetate; IFN, interferon-β; IVIg, intravenous immunoglobulins; i.th., intrathecal; Mitox, mitoxantrone; MMF, mycophenolate mofetil; MTX, methotrexate; NAT, natalizumab; p.o., per os; RTX, rituximab; TCZ, tocilizumab.